October 9, 2025 — Leads & Copy — bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) has closed definitive agreements for the purchase and sale of 720,000 shares of common stock at $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules.
WallachBeth Capital, LLC was the sole placement agent for the offering.
The company plans to use the net proceeds for working capital, to support growing sales for CyPath® Lung, its noninvasive test for lung cancer, and general corporate purposes.
The offering was made via a “shelf” registration statement on Form S-3 (File No. 333-275608) previously filed with the SEC and declared effective on November 27, 2023.
Electronic copies of the prospectus supplement and accompanying prospectus may be obtained on the SEC’s website or by contacting WallachBeth Capital, LLC.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Source: bioAffinity Technologies, Inc.
